Published 2 days ago • loading... • Updated 2 days ago

ASCO Study Abstract Shows Cizzle Bio's CIZ1B Biomarker Test for Lung Cancer Could Save $518M in Annual Medicare Costs

On May 22, 2025, Cizzle Bio revealed that their proprietary CIZ1B blood-based biomarker assay for detecting lung cancer at an early stage has the potential to reduce Medicare expenses by as much as $518 million annually.
This announcement came after a study projected that adding the CIZ1B blood test to existing lung cancer screening methods could address low participation rates by mitigating barriers such as travel, limited availability, and concerns about radiation exposure.
The simple blood test detects lung cancer with 95% sensitivity and 96% negative predictive value, potentially increasing screening participation by 15% among high-risk Medicare populations.
Research spanning over 30 years at the University of York identified the CIZ1B protein variant strongly linked to early-stage lung cancer, and the test can reduce unnecessary biopsies that account for 96% of non-cancerous nodule procedures.
Cizzle Bio, a biotechnology firm from Texas, is preparing to introduce the CIZ1B test into U.S. Clinical settings soon, with the goal of enhancing patient access, supporting healthcare professionals, and advancing lung cancer screening through innovative and practical solutions.

Insights by Ground AI

Does this summary seem wrong?

34 Articles

All

Left

Center

Right

Beatrice Daily Sun

+33 Reposted by 33 other sources

Center

ASCO Study Abstract Shows Cizzle Bio's CIZ1B Biomarker Test for Lung Cancer Could Save $518M in Annual Medicare Costs

CHICAGO, May 22, 2025 /PRNewswire/ -- Cizzle Bio, Inc. announced today the online publication of a new study abstract in conjunction with the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, projecting that its proprietary CIZ1B biomarker blood test…

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year